Strategies to detect adverse effects of antiepileptic drugs in clinical practice

Do Parkinson’s disease patients disclose their adverse events spontaneously?

“…In contrast, other AEs that are commonly caused by antiparkinsonian drugs, including cardiovascular and neuropsychiatric ones, were dramatically spontaneously underreported. This figure has Variables not included in the forward logistic regression models as they did not show significance in the bivariate tests are indicated with a dash been rarely specifically explored in PD, but is in line with previous studies in the general population [8,18] and in epileptic patients [9,19]. It is possible that studying a larger sample of patients might have provided more significant results from a statistical perspective, but the contrast between spontaneous and questionnaire results is already so spectacular in the present survey that we believe physicians should be aware of such figures for their everyday practice, even if spontaneous reporting reduces the time spent in assessing the patients.…”

“…Similarly, most pharmacovigilance systems are based on physicians' spontaneous reports of adverse drug reactions [7]. However, this method suffers from limitations related to underreporting, which can be as high as 95% in the general population [8] or in patients suffering from chronic disorders such as epilepsy [9]. There are no data about AE or adverse drug reaction underreporting in PD.…”

Comprehensive educational plan for patients with epilepsy and comorbidity (EDU-COM): a pragmatic randomised trial

“…The number of AEs declined significantly over time in both groups, similarly to what observed for the quality-of-life measurements, suggesting a possible ‘placebo effect’. Moreover, we employed unstructured interviews for the assessment of adverse effects, and this could have led to an underestimation of the number of AEs, compared to previous studies 28. For these reasons, future studies should consider a more sophisticated methodology for assessing changes in adverse effects and quality of life (eventually including ‘placebo-adjusted’ outcome measures) to clarify this issue.…”

A Review on Management of Epilepsy Complications in Health Care Practice

“…Concerned with aspects of vision functions and movements [61][62][63][64][65]  Tonic-clonic seizures loss of consciousness, body stiffening and shaking, and sometimes loss of bladder control or biting tongue.…”